Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 October 2022, 15:44 HKT/SGT
Share:
    

Source: Eisai
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
To Strengthen its Research and Development Function for Injectable Drug Formulations

TOKYO, Oct 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.

External view of EMITS

EMITS will be Eisai's global base for formulation and modality research. In recent years, Eisai's drug discovery targets have expanded to include modalities such as antibodies, antibody drug conjugates (ADCs), and nucleic acid drugs, in addition to conventional small molecule compounds. At EMITS, Eisai will strengthen its injectable drug formulation development research function and drug delivery system (DDS) development function, including liposomal and lipid nanoparticle formulations, and address the development of various modalities. The following initiatives will be implemented.

- Elevating the quality and speed of formulation process research through introduction of a state-of-the-art manufacturing data management system and utilization of AI
- Installation of facilities that also enable the manufacturing of clinical trial materials in order to manufacture investigational injection drugs in-house
- Introduction of rapid microbial testing methods for advanced microbiological control and sterility assurance
- Enhancing collaboration with the creation of flexible space that can also be used for collaborative research with external partners and technologies

Through these efforts, Eisai aims to elevate the quality of the technology and knowledge of its formulation research function, and to become a base for disseminating innovation, technology, and solutions relating to formulations. The aggregate investment in the construction of EMITS is approximately 10 billion Japanese yen.

The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing. Through the construction of EMITS, Eisai aims to elevate the quality of its formulation research and formulation manufacturing, accelerate medicine creation activities, and ultimately further its contribution to improving the benefits of patients and their families.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2022/news202273.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 1, 2022 19:09 HKT/SGT
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Nov 30, 2022 09:21 HKT/SGT
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 30, 2022 08:31 HKT/SGT
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
Nov 29, 2022 18:28 HKT/SGT
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
Nov 24, 2022 08:04 HKT/SGT
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
Nov 22, 2022 13:10 HKT/SGT
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
Nov 21, 2022 10:50 HKT/SGT
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 16, 2022 10:46 HKT/SGT
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
Nov 7, 2022 08:15 HKT/SGT
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
Nov 4, 2022 14:42 HKT/SGT
Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: